Evidence map›Paper›PMID 38902533›Full record

ArticleBritish journal of cancer2024

Late stage melanoma is hallmarked by low NLGN4X expression leading to HIF1A accumulation.

David Schörghofer, Laurenz Vock, Madalina A Mirea, Oliver Eckel, Anna Gschwendtner, Jürgen Neesen, Erika Richtig, Markus Hengstschläger, Mario Mikula

Abstract read
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Experience-mediated transcriptional memory correlates with hypoxia resistance in the nervous system of the sea hareAmerican journal of physiology. Regulatory, integrative and comparative physiology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Molecular principles underlying aggressive cancers.Signal transduction and targeted therapy · 2025
    Review
  8. Organoids in skin wound healing.Burns & trauma · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

David Schörghofer *Institute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, 1090, Austria.
Laurenz Vock *Institute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, 1090, Austria.
Madalina A MireaInstitute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, 1090, Austria.
Oliver EckelInstitute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, 1090, Austria.
Anna GschwendtnerInstitute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, 1090, Austria.
Jürgen NeesenInstitute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, 1090, Austria.
Erika RichtigDepartment of Dermatology, Medical University of Graz, 8036, Graz, Austria.ORCID http://orcid.org/0000-0002-5505-6103
Markus HengstschlägerInstitute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, 1090, Austria.
Mario MikulaInstitute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, 1090, Austria. mario.mikula@meduniwien.ac.at.ORCID http://orcid.org/0000-0001-5782-0681

Funding

Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) P32979Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) P35387-BAustrian Science Fund FWF P 32979Austrian Science Fund FWF P 35387
6 · The paper itself

Abstract

backgroundDespite ongoing research and recent advances in therapy, metastatic melanoma remains one of the cancers with the worst prognosis. Here we studied the postsynaptic cell adhesion molecule Neuroligin 4X (NLGN4X) and investigated its role in melanoma progression.

methodsWe analysed histologic samples to assess the expression and predictive value of NLGN4X in human melanoma. The oncogenic role of NLGN4X was determined by loss or gain-of-function experiments in vitro as well as by analysis of tumorspheres, which were grafted to human skin organoids derived from pluripotent stem cells. Whole genome expression analysis and validation experiments were performed to clarify the molecular mechanism.

resultsWe identified that suppression of NLGN4X down regulated the prefoldin member Von Hippel-Lindau binding protein 1 (VBP1). Moreover, loss of VBP1 was sufficient for accumulation of HIF1A and HIF1A signalling was further shown to be essential for the acquisition of migratory properties in melanoma. We re-established NLGN4X expression in late stage melanoma lines and observed decreased tumour growth after transplantation to human skin organoids generated from pluripotent stem cells. In line, we showed that high amounts of NLGN4X and its target VBP1 in human patient samples had a beneficial prognostic effect on patient survival.

conclusionIn view of these findings, we propose that decreased amounts of NLGN4X are indicative of a metastatic melanoma phenotype and that loss of NLGN4X provides a novel mechanism for HIF induction.

Indexed as

Cell Adhesion Molecules, NeuronalHypoxia-Inducible Factor 1, alpha SubunitMelanomaAnimalsCell Line, TumorCell MovementGene Expression Regulation, NeoplasticHumansMembrane ProteinsNeoplasm StagingPrognosisSkin NeoplasmsCell Adhesion Molecules, NeuronalHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitMembrane ProteinsNLGN4X protein, human

Identifiers

PMID38902533
PMCPMC11300789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.